Brigham & Women's Hospital, Department of Dermatology, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts; Dana-Farber Cancer Institute, Division of Population Sciences, Department of Medical Oncology, Boston, Massachusetts.
J Am Acad Dermatol. 2023 Jun;88(6):1282-1290. doi: 10.1016/j.jaad.2023.01.035. Epub 2023 Feb 9.
Little is known about patient-specific risk factors for skin neoplasia in individuals with Lynch syndrome (LS).
Identify clinical factors associated with development of skin neoplasms in LS.
Clinical data were systematically collected on a cohort of LS carriers (confirmed pathogenic germline variants in MLH1, MSH2, MSH6, PMS2, or EPCAM) age ≥18 undergoing clinical genetics care at Dana-Farber Cancer Institute from January 2000 to March 2020. Multivariable logistic regression was performed to evaluate clinical factors associated with skin neoplasia.
Of 607 LS carriers, 9.2% had LS-associated skin neoplasia and 15.0% had non-LS-associated skin neoplasia; 58.2% (353/607) had documentation of prior dermatologic evaluation; 29.7% (38/128) with skin neoplasms lacked a history of visceral LS-associated malignancy. LS-associated skin neoplasms were significantly associated with male sex, age, race, MLH1 pathogenic germline variants, MSH2/EPCAM pathogenic germline variants, and personal history of non-LS skin neoplasms. Non-LS-associated skin neoplasms was significantly associated with age, number of first- and second-degree relatives with non-LS-associated skin neoplasms, and personal history of LS-associated skin neoplasms.
Single-institution observational study; demographic homogeneity.
Skin neoplasms are common in individuals with LS. We identified clinical factors associated with LS- and non-LS-associated skin neoplasms. Regular dermatologic surveillance should be considered for all LS carriers.
对于林奇综合征(LS)患者,皮肤肿瘤的特定患者相关风险因素知之甚少。
确定与 LS 患者皮肤肿瘤发展相关的临床因素。
我们对 2000 年 1 月至 2020 年 3 月期间在达纳-法伯癌症研究所接受临床遗传学护理的 LS 携带者(MLH1、MSH2、MSH6、PMS2 或 EPCAM 中证实存在致病性种系变异)队列的临床数据进行了系统收集。采用多变量逻辑回归评估与皮肤肿瘤相关的临床因素。
在 607 名 LS 携带者中,9.2%患有 LS 相关皮肤肿瘤,15.0%患有非 LS 相关皮肤肿瘤;58.2%(353/607)有先前皮肤科评估的记录;29.7%(38/128)有皮肤肿瘤者缺乏内脏 LS 相关恶性肿瘤病史。LS 相关皮肤肿瘤与男性、年龄、种族、MLH1 致病性种系变异、MSH2/EPCAM 致病性种系变异以及非 LS 皮肤肿瘤个人史显著相关。非 LS 相关皮肤肿瘤与年龄、非 LS 相关皮肤肿瘤的一级和二级亲属数量以及 LS 相关皮肤肿瘤个人史显著相关。
单机构观察性研究;人口统计学同质性。
皮肤肿瘤在 LS 患者中很常见。我们确定了与 LS 和非 LS 相关皮肤肿瘤相关的临床因素。应考虑对所有 LS 携带者进行定期皮肤科监测。